Published in Br J Pharmacol on December 01, 1998
Cannabinoids and the gastrointestinal tract. Gut (2001) 1.81
Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol (2001) 1.67
Effects of cannabinoid receptor agonists on rat gastric acid secretion: discrepancy between in vitro and in vivo data. Dig Dis Sci (2006) 1.44
Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol (2003) 1.15
Central and peripheral cannabinoid modulation of gastrointestinal transit in physiological states or during the diarrhoea induced by croton oil. Br J Pharmacol (2000) 1.07
Atomoxetine for treatment of marijuana dependence: a report on the efficacy and high incidence of gastrointestinal adverse events in a pilot study. Drug Alcohol Depend (2008) 1.00
Modulation of peristalsis by cannabinoid CB(1) ligands in the isolated guinea-pig ileum. Br J Pharmacol (2000) 0.99
Gastric antisecretory role and immunohistochemical localization of cannabinoid receptors in the rat stomach. Br J Pharmacol (2002) 0.98
Investigation on the relationship between cannabinoid CB1 and opioid receptors in gastrointestinal motility in mice. Br J Pharmacol (2006) 0.97
CB1- and CB2-cannabinoid receptor-independent lipolysis induced by WIN 55,212-2 in male rat adipocytes. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.94
Role of cannabinoids in chronic liver diseases. World J Gastroenterol (2008) 0.93
Cannabinoid 1 (CB1) receptors coupled to cholinergic motorneurones inhibit neurogenic circular muscle contractility in the human colon. Br J Pharmacol (2006) 0.93
Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists. Eur J Endocrinol (2009) 0.93
Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability. Br J Pharmacol (2012) 0.90
Latest advances in novel cannabinoid CB(2) ligands for drug abuse and their therapeutic potential. Future Med Chem (2012) 0.90
AM 251 produces sustained reductions in food intake and body weight that are resistant to tolerance and conditioned taste aversion. Br J Pharmacol (2006) 0.89
Interaction between cannabinoid CB1 receptors and endogenous ATP in the control of spontaneous mechanical activity in mouse ileum. Br J Pharmacol (2009) 0.88
Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice. Neurogastroenterol Motil (2010) 0.87
Tolerance to cannabinoid response on the myenteric plexus of guinea-pig ileum and human small intestinal strips. Br J Pharmacol (2006) 0.83
Beneficial metabolic effects of CB1R anti-sense oligonucleotide treatment in diet-induced obese AKR/J mice. PLoS One (2012) 0.80
Simultaneous Activation of Induced Heterodimerization between CXCR4 Chemokine Receptor and Cannabinoid Receptor 2 (CB2) Reveals a Mechanism for Regulation of Tumor Progression. J Biol Chem (2016) 0.79
The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease. Neurogastroenterol Motil (2016) 0.77
Endocannabinoids in the Gut. Cannabis Cannabinoid Res (2016) 0.77
Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716). Naunyn Schmiedebergs Arch Pharmacol (2008) 0.76
Pharmacological characterization of cannabinoid receptor activity in the rat-isolated ileum myenteric plexus-longitudinal muscle preparation. Br J Pharmacol (2010) 0.76
(4-(Bis(4-fluorophenyl)methyl)piperazin-1-yl)(cyclohexyl)methanone hydrochloride (LDK1229): a new cannabinoid CB1 receptor inverse agonist from the class of benzhydryl piperazine analogs. Mol Pharmacol (2014) 0.75
Rimonabant, gastrointestinal motility and obesity. Curr Neuropharmacol (2012) 0.75
Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem (1995) 4.53
Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun (1990) 4.46
Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463. Kidney Int (2000) 4.43
New esters of 4-amino-5-chloro-2-methoxybenzoic acid as potent agonists and antagonists for 5-HT4 receptors. J Med Chem (1997) 2.66
Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost (2000) 2.45
A risk score for predicting perioperative blood transfusion in liver surgery. Br J Surg (2007) 2.32
Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) (1997) 2.31
The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol (2003) 2.12
The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost (1994) 2.05
Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J (1995) 1.93
Paraplegia following coeliac plexus block. Pain (1993) 1.85
The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor. J Biol Chem (1998) 1.84
Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci (1995) 1.68
Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor. FEBS Lett (1993) 1.62
Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem (1996) 1.60
In vitro inhibition of intestinal motility by phenylethanolaminotetralines: evidence of atypical beta-adrenoceptors in rat colon. Br J Pharmacol (1990) 1.58
A potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor. Life Sci (1992) 1.56
Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol (1992) 1.56
An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem (1995) 1.54
Cannabinoid-receptor expression in human leukocytes. Eur J Biochem (1993) 1.53
Subcellular localization of peripheral benzodiazepine receptors on human leukocytes. Lab Invest (1994) 1.50
Primary structure and functional expression of mouse pituitary and human brain corticotrophin releasing factor receptors. FEBS Lett (1993) 1.48
Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors. Naunyn Schmiedebergs Arch Pharmacol (1995) 1.43
Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology (Berl) (1996) 1.40
An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function. J Clin Invest (1995) 1.33
Functional identification of rat atypical beta-adrenoceptors by the first beta 3-selective antagonists, aryloxypropanolaminotetralins. Br J Pharmacol (1996) 1.32
Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett (1996) 1.32
Peripheral benzodiazepine binding sites: effect of PK 11195, 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide. I. In vitro studies. Life Sci (1983) 1.31
The immunosuppressant SR 31747 blocks cell proliferation by inhibiting a steroid isomerase in Saccharomyces cerevisiae. Mol Cell Biol (1996) 1.30
Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J Clin Invest (1993) 1.28
Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest (1996) 1.28
Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. Am J Physiol (1994) 1.27
Differentiation between two ligands for peripheral benzodiazepine binding sites, [3H]RO5-4864 and [3H]PK 11195, by thermodynamic studies. Life Sci (1983) 1.25
Characterization of specific binding sites for [3H]-staurosporine on various protein kinases. Biochem Biophys Res Commun (1990) 1.24
Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. Biochim Biophys Acta (1996) 1.23
Involvement of peripheral benzodiazepine receptors in the protection of hematopoietic cells against oxygen radical damage. Blood (1996) 1.21
Replication of hepatitis C virus in B lymphocytes (CD19+) Blood (1999) 1.18
The antiaggregating and antithrombotic activity of ticlopidine is potentiated by aspirin in the rat. Thromb Haemost (1996) 1.17
Labelling of peripheral-type benzodiazepine binding sites in human brain with [3H]PK 11195: anatomical and subcellular distribution. Brain Res Bull (1987) 1.17
Morphine tissue levels and reduction of gastrointestinal transit in rats. Correlation supports primary action site in the gut. Gastroenterology (1983) 1.16
Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. Mol Psychiatry (2004) 1.16
Inhibition of gastrointestinal transit by morphine in rats results primarily from direct drug action on gut opioid sites. J Pharmacol Exp Ther (1986) 1.15
Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int (2007) 1.14
Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system. J Pharmacol Exp Ther (1998) 1.14
Purification and characterization of the human SR 31747A-binding protein. A nuclear membrane protein related to yeast sterol isomerase. J Biol Chem (1997) 1.13
Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J Pharmacol Exp Ther (1997) 1.12
The central and peripheral influences of opioids on gastrointestinal propulsion. Annu Rev Pharmacol Toxicol (1985) 1.11
Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Lett (1995) 1.10
Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci (1996) 1.10
Reduced binding of 3 H-reserpine to the hearts of 6-hydroxydopamine-pretreated rats. Eur J Pharmacol (1972) 1.10
Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A. J Biol Chem (1996) 1.09
Characterization of two cloned human CB1 cannabinoid receptor isoforms. J Pharmacol Exp Ther (1996) 1.08
Electrophysiological and pharmacological characterization of peripheral benzodiazepine receptors in a guinea pig heart preparation. Life Sci (1984) 1.08
SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist. J Pharmacol Exp Ther (1999) 1.07
Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. Life Sci (1999) 1.07
Distribution profile and properties of peripheral-type benzodiazepine receptors on human hemopoietic cells. Life Sci (1993) 1.06
Distribution of diaphragmatic lymphatic stomata. J Appl Physiol (1985) (1991) 1.05
Evidence for nerve growth factor-potentiating activities of the nonpeptidic compound SR 57746A in PC12 cells. J Neurochem (1995) 1.04
Multiple benzodiazepine receptors: evidence of dissociation between anticonflict and anticonvulsant properties by PK 8165 and PK 9084 (two quinoline derivatives). Life Sci (1981) 1.04
Labelling of "peripheral-type" benzodiazepine binding sites in the rat brain by using [3H]PK 11195, an isoquinoline carboxamide derivative: kinetic studies and autoradiographic localization. J Neurochem (1983) 1.03
Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Sci (1996) 1.03
Inhibition of rat colon motility by stimulation of atypical beta-adrenoceptors with new gut-specific agents. Pharmacol Res Commun (1988) 1.03
2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--II. Biochemical properties. Neuropharmacology (1985) 1.02
Conservative management of cocaine-packet ingestion: experience in Milan, the main Italian smuggling center of South American cocaine. Panminerva Med (1996) 1.01
Are antihistamines sedative via a blockade of brain H1 receptors? J Pharm Pharmacol (1979) 1.00
Peripheral benzodiazepine binding sites: effect of PK 11195, 1-(2-chlorophenyl)-N-methyl-(1-methylpropyl)-3 isoquinolinecarboxamide. II. In vivo studies. Life Sci (1983) 1.00
ADP receptor induced activation of guanine nucleotide binding proteins in rat platelet membranes--an effect selectively blocked by the thienopyridine clopidogrel. Thromb Haemost (1992) 0.99
2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--I. Anticonvulsant properties. Neuropharmacology (1985) 0.98
Electrophysiological and pharmacological evidence that peripheral type benzodiazepine receptors are coupled to calcium channels in the heart. Life Sci (1985) 0.98
Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction. Br J Pharmacol (2001) 0.97
Laparoscopic liver resections for hepatocellular carcinoma. Is it a feasible option for patients with liver cirrhosis? Langenbecks Arch Surg (2008) 0.97
Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors. Eur J Pharmacol (1993) 0.97
Distribution of diaphragmatic lymphatic lacunae. J Appl Physiol (1985) (1992) 0.97
Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits. Thromb Haemost (1991) 0.97
Role of tachykinins in castor oil diarrhoea in rats. Br J Pharmacol (1997) 0.97
Peripheral benzodiazepine receptor agonists exhibit potent antiapoptotic activities. Biochem Biophys Res Commun (1999) 0.97
Differential diagnosis of Crohn's disease of the colon from ulcerative colitis: ultrastructure study with the scanning electron microscope. Int J Tissue React (1986) 0.97
Endothelin action in rat liver. Receptors, free Ca2+ oscillations, and activation of glycogenolysis. J Clin Invest (1991) 0.96
Inhibition of rat colonic motility and cardiovascular effects of new gut-specific beta-adrenergic phenylethanolaminotetralines. Life Sci (1989) 0.96
The rat beta 3-adrenergic receptor gene contains an intron. FEBS Lett (1993) 0.95
Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells. Eur J Pharmacol (1998) 0.95
Effect of the nonpeptide neurotensin antagonist, SR 48692, and two enantiomeric analogs, SR 48527 and SR 49711, on neurotensin binding and contractile responses in guinea pig ileum and colon. J Pharmacol Exp Ther (1994) 0.95